United States
Choose your country

Select to view the solutions available in your location.

Login
Patient login

Track orders, get results, manage personal information, and more.

Provider login

Order tests, track orders, get results, and more.

October 14, 2022

Dr. Paul Limburg’s Statement on the Recently Published NordICC Study in the New England Journal of Medicine

A message from Exact Sciences Corporation Chief Medical Officer of Screening

Recent media reports inaccurately implied colonoscopies are ineffective at reducing colorectal cancer deaths, per a study published in the New England Journal of Medicine. The headlines fail to tell the real story.

Based on the forty-two percent of study participants who received a colonoscopy, the mortality rate was cut in half and the risk of developing colorectal cancer decreased by 31 percent.

Colonoscopies remain a crucial tool for colorectal cancer screening. Studies also show the importance of offering more than one FDA-approved screening option, including the U.S. Preventive Services Task Force endorsed, non-invasive, at-home tests such as Cologuard®, which detects both colorectal cancers and precancerous polyps. If you’re 45 or older and at average risk for colorectal cancer, speak with your healthcare provider about your options for screening.